Literature DB >> 32015092

Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.

Ninghui Mao1, Dong Gao1, Wenhuo Hu1, Sunyana Gadal2, Haley Hieronymus1, Shangqian Wang1, Young Sun Lee1, Patrick Sullivan1, Zeda Zhang1, Danielle Choi1, Neal Rosen2,3, Charles L Sawyers1,3, Anuradha Gopalan4, Yu Chen1,3, Brett S Carver5,6,7.   

Abstract

Genomic rearrangements leading to the aberrant expression of ERG are the most common early events in prostate cancer and are significantly enriched for the concomitant loss of PTEN. Genetically engineered mouse models reveal that ERG overexpression alone is not sufficient to induce tumorigenesis, but combined loss of PTEN results in an aggressive invasive phenotype. Here, we show that oncogenic ERG repressed PI3K signaling through direct transcriptional suppression of IRS2, leading to reduced RTK levels and activity. In accordance with this finding, ERG-positive human prostate cancers had a repressed AKT gene signature and transcriptional downregulation of IRS2. Although overexpression of IRS2 activated PI3K signaling, promoting cell migration in a PI3K-dependent manner, this did not fully recapitulate the phenotype seen with loss of PTEN as PI3K signaling is not as robust as observed in the setting of loss of PTEN. Importantly, deletions of the PTEN locus, which promotes active PI3K signaling, were among the most significant copy-number alterations that co-occurred with ERG genomic rearrangements. This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote oncogenic signaling during tumor evolution. SIGNIFICANCE: This work provides insight on how initiating oncogenic events may directly influence the selection of secondary concomitant alterations to promote tumorigenesis. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32015092      PMCID: PMC7127960          DOI: 10.1158/0008-5472.CAN-19-1394

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development.

Authors:  Leila Khamzina; Philip A Gruppuso; Jack R Wands
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

2.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

3.  Use model-based Analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein-DNA interactions in embryonic stem cells.

Authors:  Tao Liu
Journal:  Methods Mol Biol       Date:  2014

4.  Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

Authors:  Johann S de Bono; Ugo De Giorgi; Daniel Nava Rodrigues; Christophe Massard; Sergio Bracarda; Albert Font; Jose Angel Arranz Arija; Kent C Shih; George Daniel Radavoi; Na Xu; Wai Y Chan; Han Ma; Steven Gendreau; Ruth Riisnaes; Premal H Patel; Daniel J Maslyar; Viorel Jinga
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

5.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

6.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

7.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.

Authors:  Ping Chi; Yu Chen; Lei Zhang; Xingyi Guo; John Wongvipat; Tambudzai Shamu; Jonathan A Fletcher; Scott Dewell; Robert G Maki; Deyou Zheng; Cristina R Antonescu; C David Allis; Charles L Sawyers
Journal:  Nature       Date:  2010-10-03       Impact factor: 49.962

8.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

9.  ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.

Authors:  Yu Chen; Ping Chi; Shira Rockowitz; Phillip J Iaquinta; Tambudzai Shamu; Shipra Shukla; Dong Gao; Inna Sirota; Brett S Carver; John Wongvipat; Howard I Scher; Deyou Zheng; Charles L Sawyers
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

10.  Organoid culture systems for prostate epithelial and cancer tissue.

Authors:  Jarno Drost; Wouter R Karthaus; Dong Gao; Else Driehuis; Charles L Sawyers; Yu Chen; Hans Clevers
Journal:  Nat Protoc       Date:  2016-01-21       Impact factor: 13.491

View more
  2 in total

Review 1.  ETS factors in prostate cancer.

Authors:  Cheng Qian; Dan Li; Yu Chen
Journal:  Cancer Lett       Date:  2022-01-14       Impact factor: 8.679

2.  Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.

Authors:  Brady G Strittmatter; Travis J Jerde; Peter C Hollenhorst
Journal:  PLoS Genet       Date:  2021-07-27       Impact factor: 6.020

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.